Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02505269 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
A Phase 2 study of Hodgkin Lymphoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 2
- Study locations
NCT02505269: Completed Phase 2 study of Hodgkin Lymphoma, sponsored by Massachusetts General Hospital.
NCT02505269 is a Phase 2 study of Hodgkin Lymphoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02505269, a Phase 2 study of Hodgkin Lymphoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others. This trial eliminates radiation therapy and reduces intensity of chemotherapy by incorporating the highly active FDA-approved targeted therapy brentuximab vedotin, an antibody-drug conjugate specifically against the lymphoma cells, combined with the standard chemotherapy drugs Adriamycin and Dacarbazine (AD).
Primary Outcome
The number of patients that achieved a complete response (CR) to therapy as assessed by the revised International Working Group Criteria. Complete response: * Lymph nodes and extralymphatic sites: Score 1, 2, or 3 with or without a residual mass on 5-point (Daeuville) scale * Bone Marrow: No evidence of FDG-avi disease * No new lesions Deauville Criteria for PET scan Interpretation in Lymphoma Five-point scale: 1. No Uptake 2. Uptake ≤ mediastinum 3. Uptake \>mediastinum but ≤ liver 4. Upta
Conditions Studied
Interventions
- DRUG Brentuximab Vedotin
- DRUG Dacarbazine
- DRUG Adriamycin
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-08-07 |
| Est. Completion | 2019-06 |
| Phase | Phase 2 |
What the finished NCT02505269 record still lists
NCT02505269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Brentuximab Vedotin is the first listed.
NCT02505269 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02505269 about?
NCT02505269 is a clinical study titled "Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma". Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others. This trial eliminates radiation therapy and reduces intensity of chemotherapy by incorporating t...
What is the current status of trial NCT02505269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2015-08-07. Estimated completion is 2019-06.
What conditions does trial NCT02505269 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT02505269?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Dacarbazine (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT02505269?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02505269 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02505269's enrollment target sits among peer trials
34 47th of 71 higher than 24 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI